Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of Pitavastatin

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 2, 2013, Pages 104-108

  Hu, Miao ^a   Mak, Valiant Wah Lun ^a   Yin, Ophelia Qi Ping ^a,b   Chu, Tanya Ten Wah ^a   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chinese; Grapefruit juice; Herb drug interaction; Pharmacogenetics; Pitavastatin; SLCO1B1

Indexed keywords

LACTONE; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SINGLE DRUG DOSE; SLCO1B1 GENE;

EID: 84876765967     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-067     Document Type: Article

References (38)

1. Fujino, H., Yamada, I., Shimada, S., Yoneda, M. and Kojima, J.: Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica, 33: 27-41 (2003).
2. Catapano, A. L.: Pitavastatin-pharmacological profile from early phase studies. Atheroscler. Suppl., 11: 3-7 (2010).
3. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H. and Sugiyama, Y.: Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol., 68: 800-807 (2005).
4. Hirano, M., Maeda, K., Shitara, Y. and Sugiyama, Y.: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther., 311: 139-146 (2004).
5. Fujino, H., Saito, T., Ogawa, S. and Kojima, J.: Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J. Pharm. Pharmacol., 57: 1305-1311 (2005).
6. Choi, M. K., Shin, H. J., Choi, Y. L., Deng, J. W., Shin, J. G. and Song, I. S.: Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica, 41: 24-34 (2011).
7. Choi, C. I., Lee, Y. J., Lee, H. I., Kim, B. H., Kim, M. J., Jang, C. G., Bae, J. W. and Lee, S. Y.: Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. Xenobiotica, 42: 496-501 (2012).
8. Deng, J. W., Song, I. S., Shin, H. J., Yeo, C. W., Cho, D. Y., Shon, J. H. and Shin, J. G.: The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet. Genomics, 18: 424-433 (2008).
9. Chung, J. Y., Cho, J. Y., Yu, K. S., Kim, J. R., Oh, D. S., Jung, H. R., Lim, K. S., Moon, K. H., Shin, S. G. and Jang, I. J.: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther., 78: 342-350 (2005).
10. Ieiri, I., Suwannakul, S., Maeda, K., Uchimaru, H., Hashimoto, K., Kimura, M., Fujino, H., Hirano, M., Kusuhara, H., Irie, S., Higuchi, S. and Sugiyama, Y.: SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacoki-netics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther., 82: 541-547 (2007).
11. Holtzman, C. W., Wiggins, B. S. and Spinler, S. A.: Role of P-glycoprotein in statin drug interactions. Pharmacotherapy, 26: 1601-1607 (2006).
12. Kirby, B. J. and Unadkat, J. D.: Grapefruit juice, a glass full of drug interactions? Clin. Pharmacol. Ther., 81: 631-633 (2007).
13. Glaeser, H., Bailey, D. G., Dresser, G. K., Gregor, J. C., Schwarz, U. I., McGrath, J. S., Jolicoeur, E., Lee, W., Leake, B. F., Tirona, R. G. and Kim, R. B.: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther., 81: 362-370 (2007).
14. de Castro, W. V., Mertens-Talcott, S., Derendorf, H. and Butterweck, V.: Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J. Agric. Food Chem., 56: 4840-4845 (2008).
15. Farkas, D. and Greenblatt, D. J.: Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin. Drug Metab. Toxicol., 4: 381-393 (2008).
16. Kantola, T., Kivisto, K. T. and Neuvonen, P. J.: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther., 63: 397-402 (1998).
17. Lilja, J. J., Kivisto, K. T. and Neuvonen, P. J.: Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther., 64: 477-483 (1998).
18. Lilja, J. J., Kivisto, K. T. and Neuvonen, P. J.: Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther., 66: 118-127 (1999).
19. Ando, H., Tsuruoka, S., Yanagihara, H., Sugimoto, K., Miyata, M., Yamazoe, Y., Takamura, T., Kaneko, S. and Fujimura, A.: Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br. J. Clin. Pharmacol., 60: 494-497 (2005).
20. Mukhtar, R. Y., Reid, J. and Reckless, J. P.: Pitavastatin. Int. J. Clin. Pract., 59: 239-252 (2005).
21. Kojima, J., Fujino, H., Yosimura, M., Morikawa, H. and Kimata, H.: Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl., 724: 173-180 (1999).
22. Shirasaka, Y., Suzuki, K., Shichiri, M., Nakanishi, T. and Tamai, I.: Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/ multidrug resistance 1. Drug Metab. Pharmacokinet., 26: 171-179 (2011).
23. Honda, Y., Ushigome, F., Koyabu, N., Morimoto, S., Shoyama, Y., Uchiumi, T., Kuwano, M., Ohtani, H. and Sawada, Y.: Effects of grapefruit juice and orange juice components on P-glycoprotein and MRP2-mediated drug efflux. Br. J. Pharmacol., 143: 856-864 (2004).
24. Parker, R. B., Yates, C. R., Soberman, J. E. and Laizure, S. C.: Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy, 23: 979-987 (2003).
25. Shirasaka, Y., Kuraoka, E., Spahn-Langguth, H., Nakanishi, T., Langguth, P. and Tamai, I.: Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J. Pharmacol. Exp. Ther., 332: 181-189 (2010).
26. Ito, K., Suzuki, H., Horie, T. and Sugiyama, Y.: Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res., 22: 1559-1577 (2005).
27. Kullak-Ublick, G. A., Ismair, M. G., Stieger, B., Landmann, L., Huber, R., Pizzagalli, F., Fattinger, K., Meier, P. J. and Hagenbuch, B.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 120: 525-533 (2001).
28. Nozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J., Sai, Y., Tsuji, A. and Yokoi, T.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther., 302: 804-813 (2002).
29. Niemi, M.: Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther., 87: 130-133 (2010).
30. Mwinyi, J., Johne, A., Bauer, S., Roots, I. and Gerloff, T.: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther., 75: 415-421 (2004).
31. Michalski, C., Cui, Y., Nies, A. T., Nuessler, A. K., Neuhaus, P., Zanger, U. M., Klein, K., Eichelbaum, M., Keppler, D. and Konig, J.: A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem., 277: 43058-43063 (2002).
32. Romaine, S. P., Bailey, K. M., Hall, A. S. and Balmforth, A. J.: The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J., 10: 1-11 (2010).
33. Wen, J. and Xiong, Y.: OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J. Clin. Pharm. Ther., 35: 99-104 (2010).
34. Jada, S. R., Xiaochen, S., Yan, L. Y., Xiaoqiang, X., Lal, S., Zhou, S. F., Ooi, L. L. and Chowbay, B.: Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur. J. Clin. Pharmacol., 63: 555-563 (2007).
35. Kalliokoski, A. and Niemi, M.: Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol., 158: 693-705 (2009).
36. Tapaninen, T., Neuvonen, P. J. and Niemi, M.: Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin. Pharmacol. Ther., 88: 339-342 (2010).
37. Rebello, S., Zhao, S., Hariry, S., Dahlke, M., Alexander, N., Vapurcuyan, A., Hanna, I. and Jarugula, V.: Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects. Eur. J. Clin. Pharmacol., 68: 697-708 (2012).
38. Uno, T. and Yasui-Furukori, N.: Effect of grapefruit juice in relation to human pharmacokinetic study. Curr. Clin. Pharmacol., 1: 157-161 (2006).